HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Italy OTC Drugs Prescription To Otc Switch

Italy Gives Adolescents OTC Access To Morning After Pill

  • News

Executive Summary

HRA Pharma's EllaOne emergency contraceptive is now available OTC for Italian adolescents under the age of 18 with the country's drug agency hoping the move will empower young women to take greater control over their lives.

You may also be interested in...



Reckitt Spies Opportunity For Global Supplements Business

RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.

Bayer Steps Up Skin Microbiome Research For Cosmetics With Partner Azitra

Bayer invests $8m in medical dermatology specialist Azitra to advance development of OTC and cosmetic products harnessing the skin microbiome.

Teva Gets EU Backing For OTC Desloratadine

Teva subsidiary Ratiopharm has secured EMA backing for the EU-wide switch of allergy drug desloratadine.

Table

View full table

Topics

Tags:
Italy OTC Drugs Prescription To Otc Switch
UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By